PharVision Advisers’s Enhabit EHAB Stock Holding History

PharVision Advisers’s Portfolio EHAB Stock Details EHAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-40,554	Closed	-$317K	–	340
2024 Q4	$317K	Buy	+40,554	New	+$308K	0.27%	133

Other funds holding EHAB

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

8KM

8 Knots Management Dallas, Texas $868M AUM 30.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

AREX Capital Management New York $60.5M AUM 45.91% 1-Year Est. Return

JPM

JANA Partners Management New York $1.67B AUM 1.66% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

PharVision Advisers's EHAB Position: Q1 2025 in Review

PharVision Advisers sold out of Enhabit (EHAB) in Q1 2025, closing a stake of 40,554 shares — an estimated $317K sold.

PharVision Advisers first reported a position in EHAB in Q4 2024 and held it in 1 quarter. The position peaked at $317K in Q4 2024. 163 funds tracked by Wall St. Rank hold EHAB as of Q1 2025.

PharVision Advisers reported no remaining Enhabit position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 40,554 Enhabit shares in Q1 2025, an estimated $317K.
PharVision Advisers first reported a position in Enhabit in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Enhabit position peaked at $317K in Q4 2024.
163 funds tracked by Wall St. Rank held Enhabit as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.